On the path toward personalized medicine: implications of pharmacogenetic studies of alcohol use disorder medications

References

• APA. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
   Google Scholar
• SAMHSA. Substance Abuse and Mental Health Services Administration. 2015 National Survey on Drug Use and Health (NSDUH). Table 5.6A—Substance Use Disorder in Past Year among Persons Aged 18 or Older, by Demographic Characteristics: numbers in Thousands, 2014 and 2015; 2015. [cited 2019 Jun 10]. Available from: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015/NSDUH-DetTabs-2015.htm#tab5-6a.
   Google Scholar
• Mokdad AH, Marks JS, Stroup DF, et al. Correction: actual causes of death in the United States, 2000. JAMA. 2005 Jan;293(3):293–294.
   PubMed Web of Science ®Google Scholar
• Sacks JJ, Gonzales KR, Bouchery EE, et al. 2010 National and state costs of excessive alcohol consumption. Am J Prev Med. 2015 Nov;49(5):e73–9.
   PubMedGoogle Scholar
• Zindel LR, Kranzler HR. Pharmacotherapy of alcohol use disorders: seventy-five years of progress. J Stud Alcohol Drugs Suppl. 2014;75(Suppl 17):79–88.
   PubMedGoogle Scholar
• Suh JJ, Pettinati HM, Kampman KM, et al. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006;26(3):290–302.
   PubMed Web of Science ®Google Scholar
• Skinner MD, Lahmek P, Pham H, et al. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS ONE. 2014;9(2):e87366.
   PubMed Web of Science ®Google Scholar
• Littleton JM. Acamprosate in alcohol dependence: implications of a unique mechanism of action. J Addict Med. 2007;1(3):115–125.
   PubMed Web of Science ®Google Scholar
• Swift RM, Aston ER. Pharmacotherapy for alcohol use disorder: current and emerging therapies. Harv Rev Psychiatry. 2015 Mar-Apr;23(2):122–133.
   PubMed Web of Science ®Google Scholar
• Ray LA, Chin PF, Miotto K. Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets. 2010 Mar;9(1):13–22.
   PubMed Web of Science ®Google Scholar
• Moos RH, Moos BS. Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction. 2006 Feb;101(2):212–222.
   PubMed Web of Science ®Google Scholar
• Schuckit MA. Alcohol-use disorders. Lancet. 2009 Feb;373(9662):492–501.
   PubMed Web of Science ®Google Scholar
• Yardley MM, Ray LA. Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. Addict Biol. 2017 May;22(3):581–615.
   PubMed Web of Science ®Google Scholar
• Reilly MT, Noronha A, Goldman D, et al. Genetic studies of alcohol dependence in the context of the addiction cycle. Neuropharmacology. 2017;122:3–21.
   PubMed Web of Science ®Google Scholar
• Bierut LJ, Saccone NL, Rice JP. et al. Defining alcohol-related phenotypes in humans. The collaborative study on the genetics of Alcoholism. Alcohol Res & Health. 2002;26(3):208–213.
   Google Scholar
• Foroud T, Edenberg HJ, Goate A, et al. Alcoholism susceptibility loci: confirmation studies in a replicate sample and further mapping. Alcohol Clin Exp Res. 2000 Jul;24(7):933–945.
   PubMed Web of Science ®Google Scholar
• Edenberg HJ, Foroud T. The genetics of alcoholism: identifying specific genes through family studies. Addict Biol. 2006 Sep;11(3–4):386–396.
   PubMed Web of Science ®Google Scholar
• Hines LM, Ray L, Hutchison K, et al. Alcoholism: the dissection for endophenotypes. Dialogues Clin Neurosci. 2005;7(2):153–163.
   PubMedGoogle Scholar
• Kranzler HR, Edenberg HJ. Pharmacogenetics of alcohol and alcohol dependence treatment. Curr Pharm Des. 2010;16(19):2141–2148.
   PubMed Web of Science ®Google Scholar
• Duncan LE, Ostacher M, Ballon J. How genome-wide association studies (GWAS) made traditional candidate gene studies obsolete. Neuropsychopharmacol. 2019;44(9):1518–1523.
   PubMed Web of Science ®Google Scholar
• Edenberg HJ, Gelernter J, Agrawal A. Genetics of alcoholism. Curr Psychiatry Rep. 2019 Mar 9;21(4):26.
   PubMed Web of Science ®Google Scholar
• Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009 Oct 8;461(7265):747–753.
   PubMed Web of Science ®Google Scholar
• Golan D, Lander ES, Rosset S. Measuring missing heritability: inferring the contribution of common variants. Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):E5272–81.
   PubMed Web of Science ®Google Scholar
• Munoz M, Pong-Wong R, Canela-Xandri O, et al. Evaluating the contribution of genetics and familial shared environment to common disease using the UK Biobank. Nat Genet. 2016 Sep;48(9):980–983.
   PubMed Web of Science ®Google Scholar
• Zuk O, Hechter E, Sunyaev SR, et al. The mystery of missing heritability: genetic interactions create phantom heritability. Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1193–1198.
   PubMed Web of Science ®Google Scholar
• Zuk O, Schaffner SF, Samocha K, et al. Searching for missing heritability: designing rare variant association studies. Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):E455–E464.
   PubMed Web of Science ®Google Scholar
• Kos MZ, Yan J, Dick DM, et al. Common biological networks underlie genetic risk for alcoholism in African- and European-American populations. Genes Brain Behav. 2013 Jul;12(5):532–542.
   PubMed Web of Science ®Google Scholar
• Walters RK, Polimanti R, Johnson EC, et al. Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. Nat Neurosci. 2018 Dec;21(12):1656–1669.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Zhou H, Kember RL, et al. Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nat Commun. 2019 Apr 2;10(1):1499.
   PubMedGoogle Scholar
• Sanchez-Roige S, Palmer AA, Fontanillas P, et al. Genome-wide association study meta-analysis of the alcohol use disorders identification test (AUDIT) in two population-based cohorts. Am J Psychiatry. 2019 Feb 1;176(2):107–118.
   PubMed Web of Science ®Google Scholar
• Hart AB, Kranzler HR. Alcohol dependence genetics: lessons learned from genome-wide association studies (GWAS) and Post-GWAS analyses. Alcohol Clin Exp Res. 2015 Aug;39(8):1312–1327.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Verweij KJ, Gillespie NA, et al. The genetics of addiction-a translational perspective. Transl Psychiatry. 2012 Jul;17(2):e140.
   Google Scholar
• Sanchez-Roige S, Palmer AA, Clarke T-K. Recent efforts to dissect the genetic basis of alcohol use and abuse. Biol Psychiatry. 2019;19: 31711–1.
   Google Scholar
• Compton WM, Dawson DA, Goldstein RB, et al. Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol. Drug Alcohol Depend. 2013 Sep 1;132(1–2):387–390.
   PubMed Web of Science ®Google Scholar
• Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med. 2008;359(7):715–721.
   PubMed Web of Science ®Google Scholar
• Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol. 2008;59(1):29–53.
   PubMed Web of Science ®Google Scholar
• Kreek MJ. Opiates, opioids and addiction. Mol Psychiatry. 1996 Jul;1(3):232–254.
   PubMed Web of Science ®Google Scholar
• Ray LA, Barr CS, Blendy JA, et al. The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res. 2012 Mar;36(3):385–394.
   PubMed Web of Science ®Google Scholar
• Huang P, Chen C, Mague SD, et al. A common single nucleotide polymorphism A118G of the mu opioid receptor alters its N-glycosylation and protein stability. Biochem J. 2012 Jan 1;441(1):379–386.
   PubMedGoogle Scholar
• Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res. 2004 Dec;28(12):1789–1795.
   PubMed Web of Science ®Google Scholar
• van den Wildenberg E, Wiers RW, Dessers J, et al. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res. 2007 Jan;31(1):1–10.
   PubMed Web of Science ®Google Scholar
• Hendershot CS, Claus ED, Ramchandani VA. Associations of OPRM1 A118G and alcohol sensitivity with intravenous alcohol self-administration in young adults. Addict Biol. 2016 Jan;21(1):125–135.
   PubMed Web of Science ®Google Scholar
• Filbey FM, Ray L, Smolen A, et al. Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin Exp Res. 2008 Jul;32(7):1113–1123.
   PubMed Web of Science ®Google Scholar
• Ray LA, Courtney KE, Hutchison KE, et al. Initial evidence that OPRM1 genotype moderates ventral and dorsal striatum functional connectivity during alcohol cues. Alcohol Clin Exp Res. 2014 Jan;38(1):78–89.
   PubMed Web of Science ®Google Scholar
• Ramchandani VA, Umhau J, Pavon FJ, et al. A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry. 2011 Aug;16(8):809–817.
   PubMed Web of Science ®Google Scholar
• Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003 Aug;28(8):1546–1552.
   PubMed Web of Science ®Google Scholar
• Anton RF, Oroszi G, O’Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135–144.
   PubMed Web of Science ®Google Scholar
• Gelernter J, Gueorguieva R, Kranzler HR, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res. 2007 Apr;31(4):555–563.
   PubMed Web of Science ®Google Scholar
• Ooteman W, Naassila M, Koeter MW, et al. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328–337.
   PubMed Web of Science ®Google Scholar
• Coller JK, Cahill S, Edmonds C, et al. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. Pharmacogenet Genomics. 2011 Dec;21(12):902–905.
   PubMed Web of Science ®Google Scholar
• Oslin DW, Leong SH, Lynch KG, et al. Naltrexone vs Placebo for the treatment of alcohol dependence: a randomized clinical trial. JAMA Psychiatry. 2015 May;72(5):430–437.
   PubMed Web of Science ®Google Scholar
• Foulds JA, Ton K, Kennedy MA, et al. OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients. Pharmacogenet Genomics. 2015 May;25(5):270–273.
   PubMed Web of Science ®Google Scholar
• Schacht JP, Randall PK, Latham PK, et al. Predictors of naltrexone response in a randomized trial: reward-related brain activation, OPRM1 genotype, and smoking status. Neuropsychopharmacology. 2017 Dec;42(13):2640–2653.
   PubMed Web of Science ®Google Scholar
• Arias AJ, Gelernter J, Gueorguieva R, et al. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. Am J Addict. 2014 May–Jun;23(3):288–293.
   PubMed Web of Science ®Google Scholar
• Arias AJ, Armeli S, Gelernter J, et al. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol Clin Exp Res. 2008 Jul;32(7):1159–1166.
   PubMed Web of Science ®Google Scholar
• Mann K, Roos CR, Hoffmann S, et al. Precision medicine in alcohol dependence: a controlled trial testing pharmacotherapy response among reward and relief drinking phenotypes. Neuropsychopharmacology. 2018 Mar;43(4):891–899.
   PubMed Web of Science ®Google Scholar
• Ashenhurst JR, Bujarski S, Ray LA. Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. Pharmacol Biochem Behav. 2012 Dec;103(2):253–259.
   PubMed Web of Science ®Google Scholar
• Koob GF, Roberts AJ, Schulteis G, et al. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res. 1998 Feb;22(1):3–9.
   PubMed Web of Science ®Google Scholar
• Bilbao A, Robinson JE, Heilig M, et al. A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice. Biol Psychiatry. 2015 May 15;77(10):850–858.
   PubMed Web of Science ®Google Scholar
• Ray R, Ruparel K, Newberg A, et al. Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A. 2011 May 31;108(22):9268–9273.
   PubMed Web of Science ®Google Scholar
• Ray LA, Green R, Roche DJO, et al. Pharmacogenetic effects of naltrexone in individuals of east asian descent: human laboratory findings from a randomized trial. Alcohol Clin Exp Res. 2018 Mar;42(3):613–623.
   PubMed Web of Science ®Google Scholar
• McGeary JE, Monti PM, Rohsenow DJ, et al. Genetic moderators of naltrexone’s effects on alcohol cue reactivity. Alcohol Clin Exp Res. 2006 Aug;30(8):1288–1296.
   PubMed Web of Science ®Google Scholar
• Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996 Nov 29;274(5292):1527–1531.
   PubMed Web of Science ®Google Scholar
• Wozniak KM, Pert A, Linnoila M. Antagonism of 5-HT3 receptors attenuates the effects of ethanol on extracellular dopamine. Eur J Pharmacol. 1990 Oct 9;187(2):287–289.
   PubMed Web of Science ®Google Scholar
• Yoshimoto K, Yayama K, Sorimachi Y, et al. Possibility of 5-HT3 receptor involvement in alcohol dependence: a microdialysis study of nucleus accumbens dopamine and serotonin release in rats with chronic alcohol consumption. Alcohol Clin Exp Res. 1996 Dec;20(9Suppl):311a–319a.
   PubMedGoogle Scholar
• Kranzler HR, Armeli S, Tennen H, et al. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J Clin Psychopharmacol. 2011 Feb;31(1):22–30.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry. 2011 Mar;168(3):265–275.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Seneviratne C, Wang XQ, et al. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. Am J Psychiatry. 2013 Sep;170(9):1020–1031.
   PubMed Web of Science ®Google Scholar
• Lawford BR, Young RM, Rowell JA, et al. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nat Med. 1995 Apr;1(4):337–341.
   PubMed Web of Science ®Google Scholar
• Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35:217–238.
   Web of Science ®Google Scholar
• Kranzler HR, Covault J, Feinn R, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014 Apr;171(4):445–452.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Wetherill R, Feinn R, et al. Posttreatment effects of topiramate treatment for heavy drinking. Alcohol Clin Exp Res. 2014 Dec;38(12):3017–3023.
   PubMed Web of Science ®Google Scholar
• Ray LA, Miranda R Jr., MacKillop J, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009 Apr;17(2):122–129.
   PubMed Web of Science ®Google Scholar
• Karpyak VM, Biernacka JM, Geske JR, et al. Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Transl Psychiatry. 2014 Oct;7(4):e462.
   Google Scholar
• Morley KC, Luquin N, Baillie A, et al. Moderation of baclofen response by a GABAB receptor polymorphism: results from the BacALD randomized controlled trial. Addiction. 2018 Dec;113(12):2205–2213.
   PubMed Web of Science ®Google Scholar
• Schuckit MA. A critical review of methods and results in the search for genetic contributors to alcohol sensitivity. Alcohol Clin Exp Res. 2018 May;42(5):822–835.
   PubMed Web of Science ®Google Scholar
• Russell MA, Schlomer GL, Cleveland HH, et al. PROSPER intervention effects on adolescents’ alcohol misuse vary by GABRA2 genotype and age. Prev Sci. 2018 Jan;19(1):27–37.
   PubMed Web of Science ®Google Scholar
• Bauer LO, Covault J, Harel O, et al. Variation in GABRA2 predicts drinking behavior in project MATCH subjects. Alcohol Clin Exp Res. 2007 Nov;31(11):1780–1787.
   PubMed Web of Science ®Google Scholar
• Eng MY, Luczak SE, Wall TL. ALDH2, ADH1B, and ADH1C genotypes in Asians: a literature review. Alcohol Res & Health. 2007;30(1):22–27.
   Google Scholar
• Yoshimura A, Kimura M, Nakayama H, et al. Efficacy of disulfiram for the treatment of alcohol dependence assessed with a multicenter randomized controlled trial. Alcohol Clin Exp Res. 2014 Feb;38(2):572–578.
   PubMed Web of Science ®Google Scholar
• Demkow U, Wolańczyk T. Genetic tests in major psychiatric disorders-integrating molecular medicine with clinical psychiatry-why is it so difficult? Transl Psychiatry. 2017;7(6):e1151–e1151.
   PubMedGoogle Scholar
• Stessman HA, Bernier R, Eichler EE. A genotype-first approach to defining the subtypes of a complex disease. Cell. 2014 Feb 27;156(5):872–877.
   PubMed Web of Science ®Google Scholar
• Schulze TG, McMahon FJ. Defining the phenotype in human genetic studies: forward genetics and reverse phenotyping. Hum Hered. 2004;58(3–4):131–138.
   PubMed Web of Science ®Google Scholar
• Hodge JC, Mitchell E, Pillalamarri V, et al. Disruption of MBD5 contributes to a spectrum of psychopathology and neurodevelopmental abnormalities. Mol Psychiatry. 2014 Mar;19(3):368–379.
   PubMed Web of Science ®Google Scholar
• Sahoo T, Theisen A, Rosenfeld JA, et al. Copy number variants of schizophrenia susceptibility loci are associated with a spectrum of speech and developmental delays and behavior problems. Genet Med. 2011 Oct;13(10):868–880.
   PubMed Web of Science ®Google Scholar
• de Goede C, Yue WW, Yan G, et al. Role of reverse phenotyping in interpretation of next generation sequencing data and a review of INPP5E related disorders. Eur J Paediatric Neurol. 2016 Mar;20(2):286–295.
   PubMed Web of Science ®Google Scholar
• George O, Koob GF. Individual differences in the neuropsychopathology of addiction. Dialogues Clin Neurosci. 2017 Sep;19(3):217–229.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Armeli S, Tennen H. Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence. Alcohol Clin Exp Res. 2012 Apr;36(4):739–744.
   PubMed Web of Science ®Google Scholar
• Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature. 2012 Sep 20;489(7416):391–399.
   PubMed Web of Science ®Google Scholar
• Richiardi J, Altmann A, Milazzo AC, et al. BRAIN NETWORKS. Correlated gene expression supports synchronous activity in brain networks. Science. 2015 Jun 12;348(6240):1241–1244.
   PubMed Web of Science ®Google Scholar
• Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci. 2007 Sep;8(9):700–711.
   PubMed Web of Science ®Google Scholar
• Sanchez-Roige S, Fontanillas P, Elson SL, et al. Genome-wide association study of alcohol use disorder identification test (AUDIT) scores in 20 328 research participants of European ancestry. Addict Biol. 2019;24(1):121–131.
   PubMed Web of Science ®Google Scholar
• Sanchez-Roige S, Palmer AA. Electronic health records are the next frontier for the genetics of substance use disorders. Trends Genet. 2019;35(5):317–318.
   PubMed Web of Science ®Google Scholar
• Rentsch CT, Fiellin DA, Bryant KJ, et al. Association between gabapentin receipt for any indication and alcohol use disorders identification test-consumption scores among clinical subpopulations with and without alcohol use disorder. Alcohol Clin Exp Res. 2019;43(3):522–530.
   PubMed Web of Science ®Google Scholar
• Treutlein J, Cichon S, Ridinger M, et al. Genome-wide association study of alcohol dependence. Arch Gen Psychiatry. 2009 Jul;66(7):773–784.
   PubMed Web of Science ®Google Scholar
• Bierut LJ, Agrawal A, Bucholz KK, et al. A genome-wide association study of alcohol dependence. Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5082–5087.
   PubMed Web of Science ®Google Scholar
• Edenberg HJ, Koller DL, Xuei X, et al. Genome-wide association study of alcohol dependence implicates a region on chromosome 11. Alcohol Clin Exp Res. 2010 May;34(5):840–852.
   PubMed Web of Science ®Google Scholar
• Kendler KS, Kalsi G, Holmans PA, et al. Genomewide association analysis of symptoms of alcohol dependence in the molecular genetics of schizophrenia (MGS2) control sample. Alcohol Clin Exp Res. 2011 May;35(5):963–975.
   PubMed Web of Science ®Google Scholar
• Heath AC, Whitfield JB, Martin NG, et al. A quantitative-trait genome-wide association study of alcoholism risk in the community: findings and implications. Biol Psychiatry. 2011 Sep 15;70(6):513–518.
   PubMed Web of Science ®Google Scholar
• Frank J, Cichon S, Treutlein J, et al. Genome-wide significant association between alcohol dependence and a variant in the ADH gene cluster. Addict Biol. 2012 Jan;17(1):171–180.
   PubMed Web of Science ®Google Scholar
• Zuo L, Gelernter J, Zhang CK, et al. Genome-wide association study of alcohol dependence implicates KIAA0040 on chromosome 1q. Neuropsychopharmacology. 2012 Jan;37(2):557–566.
   PubMed Web of Science ®Google Scholar
• Wang JC, Foroud T, Hinrichs AL, et al. A genome-wide association study of alcohol-dependence symptom counts in extended pedigrees identifies C15orf53. Mol Psychiatry. 2013 Nov;18(11):1218–1224.
   PubMed Web of Science ®Google Scholar
• McGue M, Zhang Y, Miller MB, et al. A genome-wide association study of behavioral disinhibition. Behav Genet. 2013 Sep;43(5):363–373.
   PubMed Web of Science ®Google Scholar
• Park BL, Kim JW, Cheong HS, et al. Extended genetic effects of ADH cluster genes on the risk of alcohol dependence: from GWAS to replication. Hum Genet. 2013 Jun;132(6):657–668.
   PubMed Web of Science ®Google Scholar
• Quillen EE, Chen XD, Almasy L, et al. ALDH2 is associated to alcohol dependence and is the major genetic determinant of “daily maximum drinks” in a GWAS study of an isolated rural Chinese sample. Am J Med Genet B Neuropsychiatr Genet. 2014;165b(2:103–110.
   Google Scholar
• Gelernter J, Kranzler HR, Sherva R, et al. Genome-wide association study of alcohol dependence: significant findings in African- and European-Americans including novel risk loci. Mol Psychiatry. 2014 Jan;19(1):41–49.
   PubMed Web of Science ®Google Scholar
• Lai D, Wetherill L, Bertelsen S, et al. Genome-wide association studies of alcohol dependence, DSM-IV criterion count and individual criteria. Genes Brain Behav. 2019;18(6):e12579.
   PubMed Web of Science ®Google Scholar
• Sun Y, Chang S, Wang F, et al. Genome-wide association study of alcohol dependence in male Han Chinese and cross-ethnic polygenic risk score comparison. Transl Psychiatry. 2019;9(1):249.
   PubMedGoogle Scholar
• Kim SG, Kim CM, Choi SW, et al. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl). 2009 Jan;201(4):611–618.
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Armeli S, Covault J, et al. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Addict Biol. 2013 Jan;18(1):193–201.
   PubMed Web of Science ®Google Scholar